Migraine and Work-Disability: New Treatments Reduce Work-Related Burden Among Migraine Population.

Migraine often leads to significant work disability, impacting productivity and quality of life. This study examined how new treatments can help reduce work-related limitations in migraine patients. Researchers used a specific questionnaire to measure work-related issues in patients receiving anti-CGRP monoclonal antibodies. They enrolled 175 patients from three headache centers for this study. Data was collected every three months for a year. The study focused on changes in work-related scores, medication use, and migraine days per month. Results showed that these new treatments significantly improved patients' work-related scores. This suggests that anti-CGRP therapies can effectively reduce the burden of migraines on work productivity. By addressing this issue, the study highlights the importance of targeted treatments for better work outcomes. Overall, the findings provide hope for patients struggling with migraine-related work disability and suggest potential improvements in their daily lives. Clinical relevance: This research indicates that anti-CGRP treatments can significantly improve work productivity in migraine patients.